Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Huanjing Kexue Xuebao/Acta Scientiae Circumstantiae ; 41(10):4200-4211, 2021.
Article in Chinese | Scopus | ID: covidwho-1498007

ABSTRACT

Affected by the COVID-19 epidemic, a series of lockdown control measures adopted by various regions have reduced the emission intensity of air pollutants. Taking Chengdu as an example, this study analyzed the meteorological conditions and pollution concentration characteristics in the first half of 2020 and focused on a detailed analysis of variations in ozone (O3) concentration. The results showed that: ①Compared with 2019, except for O3, all five pollutants in Chengdu showed a decreased trend, and the concentrations of NO2, CO, SO2, PM10 and PM2.5 decreased by 13.60%, 8.96%, 6.30%, 4.56%, 1.80%, respectively. On the contrary, O3 concentration increased abnormally, with the largest increase in February (35.1%) and May (36.1%). ②During the first half of 2020, the high O3 concentration level appeared earlier than in previous years (2015-2019). Meteorological conditions were more supportive to the generation of O3 also. The geopotential heights of 100 hPa and 500 hPa showed positive anomalies, the temperature and sunshine duration was higher than in previous years, and the relative humidity as well as precipitation were lower with a quiet breeze. ③The O3 formation process lasted a long time from April 25th to May 6th, mainly due to the increased emissions of O3 precursors during this period and the relatively stable weather situation, which kept the Chengdu area exposed to unfavorable weather conditions of high temperature (average temperature>30℃), low humidity (40%~60%), and quiet breeze (1.3 m•s-1) for a long time. The backward trajectories and potential sources of air pollution showed that the air quality was affected by the short-distance transportation of high-polluted air masses from the East of Chengdu and southern Sichuan. © 2021, Science Press. All right reserved.

2.
American Journal of Respiratory and Critical Care Medicine ; 203(9):1, 2021.
Article in English | Web of Science | ID: covidwho-1407555
3.
Critical Care Medicine ; 49(1):42-42, 2021.
Article in English | Web of Science | ID: covidwho-1326643
4.
Critical Care Medicine ; 49(1):122-122, 2021.
Article in English | Web of Science | ID: covidwho-1326642
5.
Earth System Science Data ; 13(6):2895-2907, 2021.
Article in English | Scopus | ID: covidwho-1280887

ABSTRACT

The COVID-19 pandemic lockdowns led to a sharp drop in socio-economic activities in China in 2020, including reductions in fossil fuel use, industry productions, and traffic volumes. The short-term impacts of lockdowns on China's air quality have been measured and reported, however, the changes in anthropogenic emissions have not yet been assessed quantitatively, which hinders our understanding of the causes of the air quality changes during COVID-19. Here, for the first time, we report the anthropogenic air pollutant emissions from mainland China by using a bottom-up approach based on the near-real-time data in 2020 and use the estimated emissions to simulate air quality changes with a chemical transport model. The COVID-19 lockdown was estimated to have reduced China's anthropogenic emissions substantially between January and March in 2020, with the largest reductions in February. Emissions of SO2, NOx, CO, non-methane volatile organic compounds (NMVOCs), and primary PM2.5 were estimated to have decreased by 27ĝ€¯%, 36ĝ€¯%, 28ĝ€¯%, 31ĝ€¯%, and 24ĝ€¯%, respectively, in February 2020 compared to the same month in 2019. The reductions in anthropogenic emissions were dominated by the industry sector for SO2 and PM2.5 and were contributed to approximately equally by the industry and transportation sectors for NOx, CO, and NMVOCs. With the spread of coronavirus controlled, China's anthropogenic emissions rebounded in April and since then returned to the comparable levels of 2019 in the second half of 2020. The provinces in China have presented nearly synchronous decline and rebound in anthropogenic emissions, while Hubei and the provinces surrounding Beijing recovered more slowly due to the extension of lockdown measures. The ambient air pollution presented much lower concentrations during the first 3 months in 2020 than in 2019 while rapidly returning to comparable levels afterward, which have been reproduced by the air quality model simulation driven by our estimated emissions. China's monthly anthropogenic emissions in 2020 can be accessed from 10.6084/m9.figshare.c.5214920.v2 (Zheng et al., 2021) by species, month, sector, and province. © Copyright:

6.
American Journal of Respiratory and Critical Care Medicine ; 203(9), 2021.
Article in English | EMBASE | ID: covidwho-1277384

ABSTRACT

Rationale: Coronavirus disease 2019 (COVID-19) is currently the third leading cause of death in the United States. During the Spring of 2020, the Commonwealth of Massachusetts, USA experienced a surge of COVID-19 ICU cases. Many of these patients developed acute renal failure (ARF) requiring renal replacement therapy (RRT) with hemodialysis (HD) or continuous veno-venous hemofiltration (CVVH) which taxed our hospital's supply of equipment and staff. The goal of our study was to identify predictors of mortality in ICU patients requiring RRT in the setting of COVID-19, should rationing of ICU care became necessary. Methods: Between March 2020 and April 2020, we prospectively collected data on patients admitted to the Lahey ICUs with severe COVID-19 who required RRT and assessed patient characteristics and mortality. Results: Thirty ICU patients were identified with severe COVID-19 requiring RRT. Twenty-seven patients (90%) required acute initiation of CVVH, while three (10%) only utilized intermittent HD during their hospitalization. Only ten (33%) survived their hospitalization. No significant difference was found between survivors and patients who died with respect to age, comorbidities (BMI, CKD, HTN, DM, alcohol use, heart disease, malignancy, COPD, asthma) or baseline creatinine. All 30 patients (100%) required mechanical ventilation (MV) and 25 (83%) developed shock requiring vasopressors prior to initiation of RRT. Seventy percent of survivors (7/10) had been on either an ACE-inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB) prior to hospitalization, compared to only 20% (4/20) who died (p=0.0147) Survivors were treated with hydroxychloroquine (HC) significantly more frequently (10/10 vs 8/20;p=0.0016) and treated with systemic corticosteroids (CS) significantly less frequently (5/10 vs 20/20;p=0.0018) than those who died. There was no difference in survival between those who received Vancomycin or Tocilizumab and those who did not. The median hospital stay was significantly longer for survivors (46 days) than for those who died (19 days;p =0.0003). Conclusion: The need for RRT in ICU patients with COVID-19 was associated with significant mortality (66%) and a significant need for MV (100%) and vasopressors (83%). The use of an ACEI or ARB prior to admission was significantly associated with improved survival, the use of CS was associated with higher mortality, and the use of HC was associated with improved survival. These latter findings go against current theories of COVID pathophysiology and may be a result of the small number of patients in our study.

7.
World Academy of Sciences Journal ; 3(2), 2021.
Article in English | Scopus | ID: covidwho-1256721

ABSTRACT

From the end of 2019, an ongoing outbreak of a new type of unexplained pneumonia caused by a novel coro- navirus, Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China. Since then, it has spread to most parts of China and worldwide, thus affecting the health of individuals worldwide. Until August 2020, >25 million cases of SARS-CoV-2 infection had been confirmed worldwide, causing >800,000 deaths. This disease was named by the World Health Organization as coronavirus disease 2019 (COVID-19). Similar to SARS and Middle East Respiratory Syndrome, which are also caused by coronavirus infections, COVID-19 mainly causes severe respiratory system damage;however, it also causes damage to multiple organs, including the gastrointestinal tract, the cardiovascular system and the nervous system. The main aim of the present review article was to summarize the current knowledge of COVID-19, such as the transmission process, diagnostic methods, pathological character- istics, potential pathogenic mechanisms and treatment measures. © 2021 Spandidos Publications. All rights reserved.

8.
Critical Care Medicine ; 49(1 SUPPL 1):122, 2021.
Article in English | EMBASE | ID: covidwho-1193957

ABSTRACT

INTRODUCTION: Variation in practice regarding the use of High Flow Nasal Cannula (HFNC) existed among hospitals during the COVID-19 pandemic. We hypothesized that patients who received HFNC prior to requiring mechanical ventilation (MV) would have improved mortality when compared to patients treated with conventional oxygen therapy (COT). METHODS: We conducted a prospective observational study of patients admitted to a tertiary care center between March and May 2020. We included consecutive adult patients with confirmed COVID-19 related ARDS who required MV. We excluded patients treated with NIV. Demographic data were collected and outcomes were censored at day 28. HFNC was initiated at the treating provider's discretion as well as availability of equipment and negative pressure rooms. Patients receiving HFNC therapy received oxygen at 20-60L/min with FiO2 to keep oxygen saturation >92%. COT was delivered with a non-rebreather mask or reservoir nasal cannula at 10-15L/min. Decision to proceed with MV was at clinician discretion. We used Student's t-test, Wilcoxon Rank-Sum, Fisher's Exact, and Chi-Square for statistical analysis. RESULTS: 92 patients were included. 58% were male and the mean age was 68±12 years. Thirty (33%) patients were treated with HFNC prior to MV. Patients in the COT group had more CAD and CHF when compared to patients in the HFNC group (13 vs 1, p=0.03 and 8 vs. 0, p=0.05). HFNC was provided for a median of 21 (IQR 9-36) hours vs. COT for 4 (IQR 1-11) hours prior to MV (p=<.0001) There was no difference in the initial PaO2/FiO2 ratio (152±62 HFNC vs. 153±67 COT, p-0.95). The mean SOFA score was significantly lower in the HFNC group compared to the COT group (6.6 vs. 7.7, p=0.05). The mortality rate was 30% in the HFNC group versus 52% in the COT group (p=0.05), with a trend toward lower mortality with HFNC (OR 0.38, 95% CI 0.12-1.15, p=0.09) after controlling for other predictors of mortality. CONCLUSIONS: Our results indicate a trend toward mortality benefit in COVID-19 patients with ARDS who were treated with HFNC compared with COT prior to intubation.

9.
Critical Care Medicine ; 49(1 SUPPL 1):42, 2021.
Article in English | EMBASE | ID: covidwho-1193802

ABSTRACT

INTRODUCTION: Our hospital experienced a surge in ICU capacity during the COVID-19 pandemic and adopted a tiered provider staffing model. We hypothesized that ICUs staffed with a tiered model would result in similar patient outcomes as ICUs staffed with a traditional intensivist model. METHODS: The study was conducted at a tertiary care center with 52 ICU beds staffed with a 24/7 intensivist coverage model. During the pandemic, ICU capacity was doubled and ICUs with COVID-19 patients were staffed by either an intensivist or by a non-intensivist under the direction of an intensivist using a tiered system. We included adult ICU patients with ARDS and suspected or confirmed COVID-19 between March and May of 2020. We collected demographics, COVID-19 and ARDS treatments, and outcomes of interest in traditionally staffed ICUs vs. ICUs staffed with a tiered model. The primary outcome was inpatient mortality. All outcomes were censored at day 28. We used Student's t-test, Wilcoxon Rank-Sum, Fisher's Exact, and Chi-Square for statistical analysis. RESULTS: A total of 138 patients were included: 66 admitted to traditionally staffed ICUs and 52 to tiered staffing ICUs. The mean age was 67±12.1 years, 63% were male, and the mean SOFA score on admission was 7.5±2.9. Baseline characteristics were similar between groups. More patients in the tiered staffing ICUs received convalescent plasma (14 vs 3%, p=0.05) and azithromycin (41 vs 23%, p=0.05). There was no difference in other COVID-19 treatments, including corticosteroids, tocilizumab, and hydroxychloroquine. ARDS treatments were similar in traditionally staffed ICUs vs tiered staffing model ICUs, including daily median tidal volumes (6.2 vs. 6.2mL/kg, p=0.95), median daily fluid balance (159 vs. 92mL, p=0.54), and use of prone ventilation (58 vs. 65%, p=0.45). There was no difference in inpatient mortality between groups (50 vs. 42%, p=0.46). Successful extubation rates were similar between groups (36 vs. 40%, p=0.71). We also found no difference in ventilator-free, ICU-free, vasopressor-free, and dialysis-free days between groups. CONCLUSIONS: Patient outcomes were similar using a traditional vs. a tiered ICU staffing model during a pandemic. Our analysis is limited by its observational nature and confounded by other healthcare team staffing models.

10.
Progr. Biomed. Opt. Imaging Proc. SPIE ; 11597, 2021.
Article in English | Scopus | ID: covidwho-1177487
11.
ACM Int. Conf. Proc. Ser. ; : 265-270, 2020.
Article in English | Scopus | ID: covidwho-999309

ABSTRACT

Objective To study the rule of Chinese medicine prescription According to the prescription novel coronavirus pneumonia;to provide reference for the treatment of epidemic diseases. Methods Through crawling 227 prescriptions of Xinguan TCM collected by Huabing data website intelligent TCM big data platform, we analyzed the web page data by using word cloud analysis, data visualization and the third-party library lxml and request of Python. Results High frequency of drug use of traditional Chinese medicine are: Huoxiang, Atractylodes, Platycodon, honeysuckle, astragalus, Scutellaria, Atractylodes macrocephala, etc. The analysis of clinical symptoms showed that the most common symptoms were fatigue, fever, white fur, cough, chest tightness, diarrhea and so on. Hebei, Sichuan, Heilongjiang, Gansu and other provinces provide more. Conclusion The novel coronavirus pneumonia and almond novel coronavirus pneumonia treatment are better. The results showed that the effective prescriptions and fever, fatigue and other common clinical manifestations, as well as the provinces with higher prescriptions, have important reference significance for the follow-up development of the new crown pneumonia. © 2020 ACM.

12.
Chinese Journal of New Drugs ; 29(16):1807-1812, 2020.
Article in Chinese | Scopus | ID: covidwho-831637

ABSTRACT

In the history of fighting the plague, traditional Chinese medicine (TCM) has the tradition of using "Universal Formula" with "cauldron boiling medicine". The practice of prevention and treatment of plague with "Universal Formula" is not only one of the important characteristics of TCM, but also deeply embodies the scientific connotation of the plague prevention and control model of "disease differentiation and treatment" combined with "syndrome differentiation and treatment". In the battle against COVID-19, a batch of contemporary anti-epidemic "Universal Formula" represented by "Hanshiyi Formula (Wuhan anti-epidemic prescription)" and "Qingfei Paidu Decoction" were used for both treatment and prevention. It covered a large number of people and had significant clinical effects. It has become a sharp weapon for TCM to intervene in anti-epidemic work. The "Universal Formula" used in the prevention and treatment of COVID-19 not only retains the essence of the traditional "Universal Formula" for anti-epidemic, but also has innovations in legislative prescriptions, drug formulations, drug distribution forms, medication guidance, and drug efficacy research, which reflects the development of the anti-epidemic with "Universal Formula". This article discussed the overview and diagnosis of the plague and treatment model of "disease differentiation and treatment" combined with "syndrome differentiation and treatment", the theoretical basis of anti-epidemic theory of "Universal Formula", and the innovation and development of the application of "Universal Formula". Under the background of science and technology, the important value and strategic path of "Universal Formula" will be used to help the in-depth development of anti-epidemic work of TCM in the face of new and sudden large-scale plagues in the future. © 2020, Chinese Journal of New Drugs Co. Ltd. All right reserved.

13.
Journal of Traditional Chinese Medicine ; 40(3):497-508, 2020.
Article in English | EMBASE | ID: covidwho-707200

ABSTRACT

The TCM protocol in the Diagnosis and Treatment Protocol for corona virus disease 2019 (COVID-19) (Trial Version 7) has been updated from previous versions. The protocol was formulated under the direct leadership of the National Administration of Traditional Chinese Medicine, based on the experience of a panel of experts, supported by evidence from fever clinics and from the outcomes of emergency (EM) observation rooms and inpatients throughout China (especially in Wuhan, Hubei Province) in combination with the latest scientific research results and data. The present interpretation of the TCM protocol is based on an overall understanding of the revised content, and aims to guide and standardize its clinical application to provide a reference for clinicians.

14.
Clin Microbiol Infect ; 26(9): 1242-1247, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-637775

ABSTRACT

OBJECTIVES: Since December 2019, the novel coronavirus disease 2019 (COVID-19) that emerged in Wuhan city has spread rapidly around the world. The risk for poor outcome dramatically increases once a patient progresses to the severe or critical stage. The present study aims to investigate the risk factors for disease progression in individuals with mild to moderate COVID-19. METHODS: We conducted a cohort study that included 1007 individuals with mild to moderate COVID-19 from three hospitals in Wuhan. Clinical characteristics and baseline laboratory findings were collected. Patients were followed up for 28 days for observation of disease progression. The end point was the progression to a more severe disease stage. RESULTS: During a follow up of 28 days, 720 patients (71.50%) had recovered or were symptomatically stable, 222 patients (22.05%) had progressed to severe disease, 22 patients (2.18%) had progressed to the critically ill stage and 43 patients (4.27%) had died. Multivariate Cox proportional hazards models identified that increased age (hazard ratio (HR) 2.56, 95% CI 1.97-3.33), male sex (HR 1.79, 95% CI 1.41-2.28), presence of hypertension (HR 1.44, 95% CI 1.11-1.88), diabetes (HR 1.82, 95% CI 1.35-2.44), chronic obstructive pulmonary disease (HR 2.01, 95% CI 1.38-2.93) and coronary artery disease (HR 1.83, 95% CI 1.26-2.66) were risk factors for disease progression. History of smoking was protective against disease progression (HR 0.56, 95% CI 0.34-0.91). Elevated procalcitonin (HR 1.72, 95% CI 1.02-2.90), urea nitrogen (HR 1.72, 95% CI 1.21-2.43), α-hydroxybutyrate dehydrogenase (HR 3.02, 95% CI 1.26-7.21) and D-dimer (HR 2.01, 95% CI 1.12-3.58) at baseline were also associated with risk for disease progression. CONCLUSIONS: This study identified a panel of risk factors for disease progression in individuals with mild to moderate COVID-19.


Subject(s)
COVID-19/diagnosis , Disease Progression , Adolescent , Adult , Age Factors , Aged , Blood Urea Nitrogen , COVID-19/physiopathology , Child , Child, Preschool , China , Comorbidity , Coronary Artery Disease , Diabetes Mellitus , Female , Fibrin Fibrinogen Degradation Products/analysis , Humans , Hydroxybutyrate Dehydrogenase/blood , Hypertension , Infant , Infant, Newborn , Male , Middle Aged , Procalcitonin/blood , Proportional Hazards Models , Pulmonary Disease, Chronic Obstructive , Risk Factors , Sex Factors , Smoking , Young Adult
15.
Zhonghua Jie He He Hu Xi Za Zhi ; 43(5): 427-430, 2020 May 12.
Article in Chinese | MEDLINE | ID: covidwho-591192

ABSTRACT

Objective: To raise awareness about 2019 novel coronavirus pneumonia (NCP) and reduce missed diagnosis rate and misdiagnosis rate by comparing the clinical characteristics between RNA positive and negative patients clinically diagnosed with NCP. Methods: From January 2020 to February 2020, 54 patients who were newly diagnosed with NCP in Wuhan Fourth Hospital were included in this study. RT-PCR method was used to measure the level of 2019-nCov RNA in pharyngeal swab samples of these patients. The patients were divided into RNA positive and negative group, and the differences of clinical, laboratory, and radiological characteristics were compared. Results: There were 31 RNA of 2019-nCov positive cases, and 23 negative cases. Common clinical symptoms of two groups were fever (80.64% vs. 86.96%) , chills (61.29% vs. 52.17%) , cough (80.64% vs. 95.65%) , fatigue (61.30% vs. 56.52%) , chest distress (77.42% vs.73.91%) . Some other symptoms were headache, myalgia, dyspnea, diarrhea, nausea and vomiting. The laboratory and radiological characteristics of two groups mainly were lymphopenia, increased erythrocyte sedimentation rate, increased C-reactive protein, increased lactate dehydrogenase, decreased oxygenation index, normal white blood cell count and bilateral chest CT involvement. There was no statistically significant difference in other clinical characteristics except for dyspnea between two groups. Conclusions: RNA positive and negative NCP patients shared similar clinical symptoms, while RNA positive NCP patients tended to have dyspnea. Therefore, we should improve the understanding of NCP to prevent missed diagnosis and misdiagnosis; In addition, more rapid and accurate NCP diagnostic approaches should be further developed.


Subject(s)
Coronavirus Infections , Pandemics , Pneumonia, Viral , RNA, Viral , Betacoronavirus/isolation & purification , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/standards , Coronavirus Infections/diagnosis , Coronavirus Infections/pathology , Diagnostic Errors/statistics & numerical data , Humans , Missed Diagnosis/statistics & numerical data , Pneumonia, Viral/diagnosis , Pneumonia, Viral/pathology , RNA, Viral/analysis , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL
...